P1, N=18, Terminated, GlaxoSmithKline | Active, not recruiting --> Terminated; The protocol was terminated on the basis of a reprioritization of organizational allocation of resources for clinical research programs.
GSK3745417 also blocked colony formation in primary AML samples from 5 donors.GSK3745417 is able to induce growth inhibition with transient compound incubation in vitro in as little as 30 minutes to 1 hour. Taken together, this data suggests a role for GSK3745417 as a therapeutic in AML/MDS indications through dual mechanisms of direct tumor cell killing and immune activation at a clinically relevant dose.The human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol.